drugset / Trial / NCT00099619

Comparing Exenatide and Insulin Glargine in Type 2 Diabetes Patients for Whom Insulin is the Next Appropriate Therapy

NCT00099619

Phase 3 Completed 138 enrolled AstraZeneca Eli Lilly and Company · collab
RandomizedCrossoverOpen-labelTreatment

Summary

This is a study with two treatment sequences and two treatment periods that will assess the safety and efficacy of exenatide treatment in patients with type 2 diabetes who have inadequate glycemic control using metformin or sulfonylurea and for whom insulin is the next appropriate step in diabetes treatment.

Timeline

Start
2004-09
Primary completion
2005-08
Completion
2005-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Exenatide Peptide 10 ug Subcutaneous
Subject insulin glargine Protein / enzyme biologic Subcutaneous